MX2015007015A - Peptidos sema5b y vacunas que contienen los mismos. - Google Patents
Peptidos sema5b y vacunas que contienen los mismos.Info
- Publication number
- MX2015007015A MX2015007015A MX2015007015A MX2015007015A MX2015007015A MX 2015007015 A MX2015007015 A MX 2015007015A MX 2015007015 A MX2015007015 A MX 2015007015A MX 2015007015 A MX2015007015 A MX 2015007015A MX 2015007015 A MX2015007015 A MX 2015007015A
- Authority
- MX
- Mexico
- Prior art keywords
- peptides
- sema5b
- methods
- antigen
- well
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 10
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 10
- 229960005486 vaccine Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 3
- 230000001939 inductive effect Effects 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 101000654679 Homo sapiens Semaphorin-5B Proteins 0.000 abstract 2
- 102100032780 Semaphorin-5B Human genes 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 101100149250 Homo sapiens SEMA5B gene Proteins 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
- 206010041067 Small cell lung cancer Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000005809 anti-tumor immunity Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 229940023041 peptide vaccine Drugs 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000019465 refractory cytopenia of childhood Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describen en la presente vacunas de péptido contra el cáncer. En particular, se proporcionan péptidos epitópicos aislados derivados del gen SEMA5B que inducen CTLs y de esta manera son adecuados para el uso en el contexto de la inmunoterapia para el cáncer. Los péptidos inventivos abarcan tanto péptidos derivados de SEMA5B como versiones modificadas de los mismos, en los cuales uno, dos o varios aminoácidos se sustituyen, se suprimen, se insertan o se agregan, con la condición de que tales versiones modificadas retengan la inducibilidad de CTL requerida de las secuencias originales. Se proporcionan adicionalmente polinucleótidos que codifican tales péptidos así como composiciones farmacéuticas que incluyen cualquiera de tales péptidos o polinucleótidos como agentes activos. También se proporcionan las células que presentan antígeno y CTLs aislados que fijan como objetivo tales péptidos, así como métodos para inducir la célula que presenta antígeno, o CTL. Adicionalmente, la presente invención proporciona métodos para el tratamiento y/o profilaxis (es decir, prevención) de cánceres (tumores) tales como cáncer de esófago, NSCLC, RCC y SCLC, y/o la prevención de una recurrencia metastásica o post-operativa del mismo, así como métodos para inducir CTLs, métodos para inducir inmunidad anti-tumor, usando los péptidos derivados de SEMA5B, polinucleótidos que codifican los péptidos, o células que presentan antígeno que presentan los péptidos, o las composiciones farmacéuticas de la presente invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261733279P | 2012-12-04 | 2012-12-04 | |
| PCT/JP2013/007051 WO2014087626A1 (en) | 2012-12-04 | 2013-12-02 | Sema5b peptides and vaccines containing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015007015A true MX2015007015A (es) | 2015-09-28 |
Family
ID=50883068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015007015A MX2015007015A (es) | 2012-12-04 | 2013-12-02 | Peptidos sema5b y vacunas que contienen los mismos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150322112A1 (es) |
| JP (1) | JP2016502499A (es) |
| KR (1) | KR20150091311A (es) |
| CN (1) | CN105814073A (es) |
| AU (1) | AU2013356143A1 (es) |
| BR (1) | BR112015012234A2 (es) |
| CA (1) | CA2892369A1 (es) |
| IL (1) | IL238788A0 (es) |
| MX (1) | MX2015007015A (es) |
| RU (1) | RU2015126849A (es) |
| SG (1) | SG11201503918XA (es) |
| TW (1) | TW201431874A (es) |
| WO (1) | WO2014087626A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016143814A1 (ja) * | 2015-03-09 | 2016-09-15 | 日本電気株式会社 | Ｍｕｃ１由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
| GB201505585D0 (en) * | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002074237A2 (en) * | 2001-03-19 | 2002-09-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of kidney cancer |
| CN103951745A (zh) * | 2002-09-12 | 2014-07-30 | 肿瘤疗法科学股份有限公司 | Kdr肽和包括该肽的疫苗 |
| DE10344799A1 (de) * | 2003-09-26 | 2005-04-14 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| DE102005013846A1 (de) * | 2005-03-24 | 2006-10-05 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| WO2007013575A2 (en) * | 2005-07-28 | 2007-02-01 | Oncotherapy Science, Inc. | Method for diagnosing and treating renal cell carcinoma |
| TW201425333A (zh) * | 2007-04-11 | 2014-07-01 | Oncotherapy Science Inc | 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗 |
| TW200932260A (en) * | 2007-11-28 | 2009-08-01 | Oncotherapy Science Inc | STAT3 epitope peptides |
| TW201136604A (en) * | 2009-12-14 | 2011-11-01 | Oncotherapy Science Inc | TMEM22 peptides and vaccines including the same |
| SG10201502791YA (en) * | 2010-04-09 | 2015-05-28 | Oncotherapy Science Inc | Cdca5 Peptides And Vaccines Including The Same |
| TW201302800A (zh) * | 2011-06-10 | 2013-01-16 | 腫瘤療法 科學股份有限公司 | Ｓｅｍａ５ｂ胜肽及含其之疫苗 |
-
2013
- 2013-12-02 RU RU2015126849A patent/RU2015126849A/ru not_active Application Discontinuation
- 2013-12-02 US US14/648,433 patent/US20150322112A1/en not_active Abandoned
- 2013-12-02 CA CA2892369A patent/CA2892369A1/en not_active Abandoned
- 2013-12-02 MX MX2015007015A patent/MX2015007015A/es unknown
- 2013-12-02 BR BR112015012234A patent/BR112015012234A2/pt not_active IP Right Cessation
- 2013-12-02 WO PCT/JP2013/007051 patent/WO2014087626A1/en not_active Ceased
- 2013-12-02 AU AU2013356143A patent/AU2013356143A1/en not_active Abandoned
- 2013-12-02 KR KR1020157013803A patent/KR20150091311A/ko not_active Withdrawn
- 2013-12-02 SG SG11201503918XA patent/SG11201503918XA/en unknown
- 2013-12-02 CN CN201380070255.9A patent/CN105814073A/zh active Pending
- 2013-12-02 JP JP2015528112A patent/JP2016502499A/ja active Pending
- 2013-12-03 TW TW102144180A patent/TW201431874A/zh unknown
-
2015
- 2015-05-13 IL IL238788A patent/IL238788A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150091311A (ko) | 2015-08-10 |
| US20150322112A1 (en) | 2015-11-12 |
| TW201431874A (zh) | 2014-08-16 |
| IL238788A0 (en) | 2015-06-30 |
| SG11201503918XA (en) | 2015-06-29 |
| JP2016502499A (ja) | 2016-01-28 |
| AU2013356143A1 (en) | 2015-06-04 |
| WO2014087626A1 (en) | 2014-06-12 |
| CA2892369A1 (en) | 2014-06-12 |
| BR112015012234A2 (pt) | 2017-08-15 |
| RU2015126849A (ru) | 2017-01-12 |
| CN105814073A (zh) | 2016-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010014044A (es) | Peptidos de epitope cdca1 y vacunas que contienen los mismos. | |
| PH12021551208A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| PH12015502638A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| MA39907A (fr) | Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam) | |
| BR112015021828A2 (pt) | Peptídeos de kntc2 e vacinas que contêm os mesmos | |
| PH12014500720A1 (en) | Topk peptides and vaccines including the same | |
| MX2013014489A (es) | Peptidos sema5b y vacunas que incluyen los mismos. | |
| MX2012011668A (es) | Peptidos cdca5 y vacunas que incluyen los mismos. | |
| MX362912B (es) | Péptidos ube2t y vacunas que incluyen los mismos. | |
| MX2011012013A (es) | Peptidos ttk y vacunas que incluyen los mismos. | |
| EP4219525A3 (en) | Foxm1-derived peptide, and vaccine including same | |
| MX2015007015A (es) | Peptidos sema5b y vacunas que contienen los mismos. | |
| EP4353321A3 (en) | Koc1-derived peptide and vaccine including same | |
| MX2011010191A (es) | Peptidos c6orf167 y vacunas que continen los mismos. | |
| MX2012011385A (es) | Peptidos ect2 y vacunas que los incluyen. | |
| EP2545171A4 (en) | HJURP PEPTIDES AND VACCINES CONTAINING THEM | |
| EP3848383A3 (en) | Urlc10-derived peptide and vaccine containing same | |
| EP4282883A3 (en) | Cdca1-derived peptide and vaccine containing same | |
| MX2012011666A (es) | Peptidos cluap1 y vacunas que incluyen los mismos. | |
| PH12012501935A1 (en) | Ect2 peptides and vaccines including the same | |
| EA202090821A1 (ru) | Новый метод иммунотерапии нескольких видов опухолей, таких как рак легкого, включая нмрл | |
| MY194653A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| MY194244A (en) | Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc | |
| MY194241A (en) | Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including NSCLC | |
| MY193910A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc |